12/3
07:00 am
btai
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Neutral
Report
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
11/20
03:36 am
btai
Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones [Yahoo! Finance]
Low
Report
Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones [Yahoo! Finance]
11/12
08:19 am
btai
BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84 [Seeking Alpha]
Medium
Report
BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84 [Seeking Alpha]
11/12
07:00 am
btai
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
High
Report
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
10/24
11:38 am
btai
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
10/14
07:53 am
btai
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes [Yahoo! Finance]
Low
Report
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes [Yahoo! Finance]
10/14
07:00 am
btai
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
Low
Report
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
10/13
07:42 am
btai
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation [Yahoo! Finance]
Low
Report
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation [Yahoo! Finance]
10/13
07:00 am
btai
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
Low
Report
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
9/18
07:00 am
btai
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
Low
Report
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
9/15
08:06 am
btai
BioXcel Therapeutics (NASDAQ:BTAI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
BioXcel Therapeutics (NASDAQ:BTAI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/12
08:03 am
btai
BioXcel Therapeutics (NASDAQ:BTAI) had its price target raised by analysts at Mizuho from $2.00 to $4.00. They now have a "neutral" rating on the stock.
Medium
Report
BioXcel Therapeutics (NASDAQ:BTAI) had its price target raised by analysts at Mizuho from $2.00 to $4.00. They now have a "neutral" rating on the stock.
9/10
06:45 pm
btai
BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) [Seeking Alpha]
Medium
Report
BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript) [Seeking Alpha]
9/10
06:45 am
btai
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia [Yahoo! Finance]
Medium
Report
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia [Yahoo! Finance]
9/10
06:30 am
btai
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
Medium
Report
BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia